Import Alert 54-15 lets FDA detain dietary supplements and bulk ingredients that are or contain kratom (Mitragyna speciosa) from listed firms without examining them. FDA considers kratom a new dietary ingredient with no adequate safety evidence. Capsules, leaf powder, teas, extracts and 7-OH tablets are on it. Unlike most alerts, there is rarely a path for a product that really contains kratom.
Listed on 54-15? Send us the firm name, product and FDA notice. We review whether the listing is correct and what options you have.
Get a 54-15 Case Review| Item | Import Alert 54-15 |
|---|---|
| Official title | DWPE of Dietary Supplements and Bulk Dietary Ingredients That Are or Contain Mitragyna speciosa or Kratom |
| Basis | New dietary ingredient under section 413(d) with no adequate safety information |
| Charge | Section 402(f)(1)(B), refusal under 801(a)(3); code UNSFDIETSP |
| Forms | Capsules, leaves, powders, resins, extracts, liquids and tablets |
| Countries | Canada, Indonesia, Malaysia, Philippines, Thailand, United States |
| Related alert | Import Alert 66-41 for products marketed as drugs |
Details follow the current text of Import Alert 54-15, published August 17, 2026.
Kratom capsules and 7-OH tablets.
Crushed and powdered dried leaves.
Whole, processed and dried leaves.
Teas made from kratom leaf.
Leaf extracts, resins and mitragynine extract.
Bulk liquids made from leaf extracts.
The alert gives no release route for products that contain kratom. If you believe a detained product does not contain kratom, send the FDA Division compliance office in the notice the formulation, supplier documents and lab identity testing. Otherwise the usual outcomes are export or destruction under FDA supervision.
The alert sets no removal criteria. FDA's general guidance in RPM Chapter 9-8 applies: the firm must show the conditions behind the listing are resolved, for example that it no longer ships kratom products to the U.S. or that a listed product was misidentified. Requests can go to Importalerts2@fda.hhs.gov.
FDA's framework is in RPM Chapter 9-8; FDA removal guidance explains what a request should include.
Removal help for food and supplements.
New dietary ingredients.
Supplements with hidden drugs.
Supplement registration and labeling.
Check claims and ingredient labeling.
FDA hold statuses and release steps.
We review whether the listing is correct, explain the realistic options for detained shipments and prepare a request where one is justified. We are an independent compliance firm, not FDA or a law firm, and no one can guarantee FDA's decision.
Contact our specialists, email info@fdaregistrationassistance.com, or call +1 (928) 275-8333. Import alert removal · Supplement services · Contact.
Get a 54-15 Case ReviewFDA Registration Assistance is a private consulting firm, not FDA or any government agency. FDA registration is not FDA approval, clearance or certification.
Import Alert 54-15 is titled "Detention Without Physical Examination of Dietary Supplements and Bulk Dietary Ingredients That Are or Contain Mitragyna speciosa or Kratom." It lets FDA detain listed kratom products without examining each shipment.
FDA considers kratom a new dietary ingredient, because it knows of no evidence it was marketed as a dietary ingredient in the U.S. before October 15, 1994, and finds no adequate evidence it can be reasonably expected to be safe. The alert cites literature on toxicity in multiple organ systems and serious side effects.
The product appears to be a dietary supplement or contain a new dietary ingredient with inadequate information to provide reasonable assurance it does not present a significant or unreasonable risk of illness or injury. It is adulterated under section 402(f)(1)(B) and subject to refusal under section 801(a)(3). The OASIS code is UNSFDIETSP.
Mitragyna speciosa, mitragynine extract, biak-biak, cratom, gratom, ithang, kakuam, katawn, kedemba, ketum, krathom, krton, mambog, madat, Maeng da leaf, nauclea, Nauclea speciosa and thang.
Capsules, whole and processed leaves, leaf resins, extracts, powdered leaves, bulk liquids made from leaf extracts, kratom teas and 7-OH tablets.
The Red List covers six countries: Canada, Indonesia, Malaysia, the Philippines, Thailand and the United States.
Open Import Alert 54-15 and search the Red List by country and firm name. Each entry shows the product and the date it was added. Check before every shipment season, since the alert is updated often.
The alert gives no release route for products that contain kratom. If a product does not actually contain kratom, you can send the FDA Division compliance office the formulation, supplier documents and identity testing. Otherwise the shipment is usually exported or destroyed under FDA supervision.
The alert does not describe that route, and FDA states it has no information establishing kratom's safety as a dietary ingredient. For how FDA handles other unsafe new dietary ingredients, see Import Alert 54-18.
The alert sets no removal criteria. Under FDA's general guidance in RPM Chapter 9-8, the firm must show the conditions behind the listing are resolved, for example that a listed product was misidentified or that it no longer ships kratom products to the U.S.
Yes. The alert tells FDA staff to watch for labeling or marketing suggesting kratom products are unapproved or misbranded drugs, and notes that Import Alert 66-41 may apply.
The Red List includes a 7-OH tablet product. Products containing kratom compounds marketed as supplements can be detained under this alert.
The alert lists the Division of Import Operations at (301) 796-0356 or Imports@fda.hhs.gov, FDAPRIVATELABIMPORTALERTS@fda.hhs.gov for science and method questions, and HFP-OCE-Imports@fda.hhs.gov for policy questions.
We can review whether a listing is correct and explain your options, but we cannot help get kratom products into the U.S. as dietary supplements while FDA's position stands. We will tell you plainly if there is no realistic path.
No. FDA makes every removal decision. We are an independent compliance firm, not FDA or a law firm. We help you build a complete, well-documented request.
Tell us what your company makes, sells, or distributes, where each product is manufactured or packed, your U.S. importer or buyer arrangement, label readiness, and target shipment date.
Submitting this inquiry does not purchase a service or authorize paid work. Our team can discuss the scope and required materials before you commission assistance. Fields marked with an asterisk are required.